Extrahepatic manifestations of HCV contribute to its increased overall mortality rate in those infected relative to those who aren’t; associated cardiovascular, neoplastic and renal manifestations can contribute significantly to a patient’s truncated lifespan beyond liver-related morbidity. This webinar will address the recognition and the treatment of extrahepatic manifestations of chronic HCV infection. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Miklos Z. Molnar Dr. Miklos Z.

Lorenzo De Marchi, Cindy J. Wang, Nikolaos J. Skubas, Rishi Kothari, Jeron Zerillo, Kathirvel Subramaniam, Guy E. Efune, Michelle Y.C. Braunfeld, Susan Mandel – 19 May 2020 – More anesthesiologists are routinely using transesophageal echocardiography (TEE) during liver transplant surgery, but the effects on patient outcome are unknown. Transplant anesthesiologists are therefore uncertain if they should undergo additional training and adopt TEE.

Torsten J. Selck, Julia Bök, Ramona Amintavakoli – 19 May 2020

Manuela Cesaretti, Raffaele Brustia, Claire Goumard, François Cauchy, Nicolas Poté, Federica Dondero, Catherine Paugam‐Burtz, François Durand, Valerie Paradis, Alberto Diaspro, Leonardo Mattos, Olivier Scatton, Olivier Soubrane, Sara Moccia – 19 May 2020 – The worldwide implementation of a liver graft pool using marginal livers (ie, grafts with a high risk of technical complications and impaired function or with a risk of transmitting infection or malignancy to the recipient) has led to a growing interest in developing methods for accurate evaluation of graft quality.

Pegah Golabi, James M. Paik, Tamoore Arshad, Youssef Younossi, Alita Mishra, Zobair M. Younossi – 19 May 2020 – Although nonalcoholic fatty liver disease (NAFLD) is associated with obesity, it can also occur in lean and metabolically normal individuals. Our aim was to determine the effect of different combinations of abdominal adiposity and overall adiposity on the mortality of NAFLD. The Third National Health and Nutrition Examination Survey with mortality data from the National Death Index were used. NAFLD was defined as steatosis without other liver diseases.

Rebecca A. Sosa, Allyson Q. Terry, Fady M. Kaldas, Yi‐Ping Jin, Maura Rossetti, Takahiro Ito, Fang Li, Richard S. Ahn, Bita V. Naini, Victoria M. Groysberg, Ying Zheng, Antony Aziz, Jessica Nevarez‐Mejia, Ali Zarrinpar, Ronald W. Busuttil, David W. Gjertson, Jerzy W. Kupiec‐Weglinski, Elaine F. Reed – 19 May 2020

Ken Yoshida, Kazuha Yokota, Yukinobu Kutsuwada, Kazuhiro Nakayama, Kazuhisa Watanabe, Ayumi Matsumoto, Hiroshi Miyashita, Seik‐soon Khor, Katsushi Tokunaga, Yosuke Kawai, Masao Nagasaki, Sadahiko Iwamoto – 19 May 2020 – Nonalcoholic fatty liver disease (NAFLD) is supposed to manifest its metabolic phenotype in the liver, but it is common to have lean individuals diagnosed with NAFLD, known as lean NAFLD. We conducted a two‐stage analysis to identify NAFLD‐associated loci in Japanese patients.

Joseph F. Pisa, Robert S. Brown, Petra Hirsova, Robert E. Schwartz, Tejasav S. Sehrawat, Nicholas W. Russo, Enis Kostallari, Zaid H. Tafesh, Brett Fortune, Hirsh D. Trivedi, Daryl T.Y. Lau, Angel Morales‐Santiago, Joel Wedd, Samuel C. Buchl, Jessica L. Maiers – 18 May 2020

Brian T. Lee, Kathan Chintamaneni, Neil Kaplowitz – 18 May 2020

Meritxell Ventura‐Cots, Juan G. Abraldes, Ramon Bataller – 17 May 2020